Foscavir in Resistant Herpesvirus Infections: When to Use It

Introduction

Foscavir is an antiviral medicine used for treating infections caused by certain viruses, especially in people whose immune systems are weak or compromised. It becomes particularly important in cases where standard antiviral treatments fail or when viruses become resistant. Because of its potency and specific uses, Foscavir is given under close medical supervision and plays a significant role in managing resistant or severe viral infections.¹

Understanding Herpesvirus Infections in Immunocompromised Patients 

When treatments like cytolytic and cytotoxic drugs weaken the body's defenses, even normal resident microbes of the skin, gut, and environment, along with viruses already latent in the body such as the human herpesviruses, can become highly pathogenic. This shift increases the number of patients experiencing exaggerated herpetic infections that may become life threatening. 2 

Early recognition of infection, rapid and specific diagnosis, and appropriate antimicrobial therapy are critical for managing immunocompromised patients. Among the herpesviruses, cytomegalovirus, varicella-zoster virus, and herpes simplex virus cause significant medical and diagnostic problems. In healthy individuals, these infections are usually benign, but in immunocompromised hosts they can progress to chronic mucocutaneous infections, esophagitis, hepatitis, pneumonitis, encephalitis, or prolonged mononucleosis-like illness. Varicella-zoster virus may present as chickenpox or shingles, and both primary and recurrent infections can lead to pneumonitis, encephalitis, and hepatitis. Cytomegalovirus is strongly associated with severe pneumonitis, especially in bone marrow transplant recipients, where mortality is high, and has also been linked to graft rejection in renal transplants.2

Why Resistance Develops Against Standard Antivirals

Antiviral resistance becomes more common when the immune system cannot fully suppress the virus, allowing it to keep multiplying. Prolonged exposure to antiviral medicines encourages resistant strains to emerge. Resistance can present as persistently high viral levels or worsening symptoms even during treatment. 

This problem is especially frequent in transplant patients who require long-term antiviral therapy and experience extended periods of weakened immunity.3,4

What Is Foscavir?

Foscavir (foscarnet) is an FDA-approved antiviral medicine used to treat cytomegalovirus (CMV) retinitis in AIDS patients and herpes simplex virus (HSV) infections that do not respond to acyclovir. ¹ It is also used when CMV does not respond to ganciclovir. ¹

It is given intravenously because it is not absorbed well through the stomach. ¹ Foscavir does not work against HIV. ¹

Mechanism of Action in Resistant Viral Strains

Foscavir is a pyrophosphate analog that attaches to the viral DNA polymerase enzyme and stops the DNA chain from extending. Normally, the enzyme removes pyrophosphate to continue building DNA, but Foscavir blocks this step, stopping viral replication. ¹

It mainly targets viral enzymes but can affect human DNA polymerase only at very high doses, which are rarely required. Resistance to Foscavir may arise due to mutations in the UL54 gene. ¹

Clinical Scenarios Where Foscavir Is Indicated

Foscavir is indicated in cases where first-line antivirals fail, especially in:

• Acyclovir-resistant HSV infections in immunocompromised patients¹

• Ganciclovir-resistant CMV infections¹

• CMV retinitis in AIDS patients¹

It may also be used off-label for severe herpesvirus infections such as varicella or zoster infections resistant to standard therapy. In unique cases, Foscavir can be injected into the eye for viral eye infections under expert supervision. ¹

Clinical reports also show that induction therapy with foscarnet leads to improvement in many patients, although relapse often occurs within a month, requiring maintenance therapy. Some patients have even continued Foscavir at home until their immune system improved enough to control the infection.5

Benefits and Limitations of Foscavir Use

Benefits:

• Effective when standard antivirals fail due to resistance¹

• Targets viral DNA polymerase directly¹

• Can be combined with other antivirals for enhanced effect5

• Helpful as induction and maintenance therapy in transplant patients5

Limitations:

• Intravenous-only administration¹

• Monitoring required because of kidney and electrolyte effects¹

• Resistance can still occur in certain viral mutations¹

• High relapse rates without maintenance therapy5

Dosing and Monitoring Considerations

Foscavir must be administered slowly through IV infusion using a controlled pump. Dosage depends on age, weight, infection severity, and immune status. ¹

Monitoring includes:

• 24-hour creatinine clearance before and during therapy¹

• Frequent kidney function checks¹

• Baseline and weekly electrolytes (calcium, magnesium, sodium, potassium, phosphorus)¹

• Baseline and regular ECGs for cardiac risks¹

• Hydration assessment before infusion¹

• Complete blood count to track blood cell levels¹

These steps help detect early toxicity and adjust the dose as needed.

Safety Profile and Common Adverse Effects

Common side effects include nausea, stomach discomfort, electrolyte imbalances, and kidney-related issues.¹

Kidney complications may occur due to direct effects on kidney cells or crystal formation inside the kidneys but are usually reversible when identified early. Electrolyte disturbances such as low calcium or magnesium levels can cause cramps or fatigue.¹

More serious effects may include seizures, genital ulcers, anemia, and QT prolongation.¹

When Foscavir May Not Be the Right Option

Foscavir may not be suitable for patients who have:

• Severe kidney problems or are on dialysis¹

• Significant heart rhythm abnormalities or abnormal EKGs¹

• Uncorrected electrolyte imbalances¹

• A history of seizures¹

• Known hypersensitivity reactions such as anaphylaxis¹

It should be used cautiously in elderly patients, pregnant women, and children due to limited safety data and potential effects on bones and teeth.¹

Future Directions in Resistant Virus Management

Research shows that combining antiviral drugs that target different steps in the viral life cycle can slow resistance development and improve outcomes. Such strategies have shown success in other infections like HIV and hepatitis.

Another finding is that some resistance mutations weaken the virus, and pairing antivirals with opposite resistance patterns can still suppress the infection effectively.6

These insights may help refine treatment strategies for resistant herpesvirus infections in the future.

Conclusion

Foscavir remains a vital antiviral option for managing resistant herpesvirus infections, especially in immunocompromised patients. Its targeted mechanism of action makes it effective when standard antivirals fail. Close monitoring, proper hydration, and awareness of side effects are essential for safe use. Ongoing advances in combination therapy and resistance research may further improve patient outcomes.1-6

Related Blog: Foscavir: Uses, Warnings, Interactions & FAQs

FAQs

1. When is Foscavir used for herpesvirus infections? 
Foscavir is used when HSV infections do not respond to acyclovir or when CMV infections do not respond to ganciclovir.¹

2. Why is Foscavir important for immunocompromised or transplant patients? 
These patients have weakened immune systems, making them more prone to viral reactivation and resistant infections that require stronger antivirals like Foscavir.²

3. How is Foscavir given? 
It is administered intravenously because it is not absorbed well orally.¹

4. What precautions are needed during treatment? 
Regular kidney tests, electrolyte monitoring, ECG checks, hydration assessment, and blood counts are essential to detect side effects early.¹

References

1. Garikapati S, Nguyen M. Foscarnet. [Updated 2024 Oct 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556108/ 

2. Whitley RJ. Herpesvirus Infections in the Immunocompromised Host: Diagnosis and Management. In: Infections in the Immunocompromised Host. Home; pp. 95-118.

3. Kotton CN, Kuehnert MJ, Fishman JA. Organ Transplantation, Risks. Reference Module in Biomedical Sciences. 2015:B978-0-12-801238-3.02629-5. doi: 10.1016/B978-0-12-801238-3.02629-5. Epub 2015 Mar 6. PMCID: PMC7157449. 

4. Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010 Jun;24(2):413-37. doi: 10.1016/j.idc.2010.01.001. Corrected and republished in: Infect Dis Clin North Am. 2010 Sep;24(3):809-33. doi: 10.1016/j.idc.2010.07.001. PMID: 20466277; PMCID: PMC2871161. 

5. Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 1991 Jan;41(1):104-29. doi: 10.2165/00003495-199141010-00009. PMID: 1706982. 

6. Aw, D.Z.H., Zhang, D.X. & Vignuzzi, M. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals. npj Antimicrob Resist 3, 54 (2025). https://doi.org/10.1038/s44259-025-00125-z